Home > Insider Trading > Filing (0000950170-24-041844)

Filing Details

Accession Number:: 0000950170-24-041844
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-04-04 16:30:49
Reporting Period:: 2024-04-02

Accepted Time:: 2024-04-04 16:30:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1782303	Boundless Bio Inc.	BOLD	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569248	Kristina Burow	C/O Boundless Bio, Inc. 9880 Campus Point Drive, Suite 120 San Diego CA 92121		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-04-02	589,743	$0.00	617,092	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	787,545	$0.00	828,570	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	1,048,433	$0.00	1,048,433	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	66,667	$16.00	683,759	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	133,333	$16.00	1,181,766	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-02	424,908	$0.00	424,908	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-02	586,080	$0.00	586,080	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-02	454,212	$0.00	454,212	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2024-04-02	227,920	$0.00	227,920	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2024-04-02	164,835	$0.00	164,835	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2024-04-02	201,465	$0.00	201,465	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2024-04-02	366,301	$0.00	366,301	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
These shares are held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
These shares are held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC ("AVP IX MDs"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose.
Reflects shares purchased by ARCH IX in the Issuer's initial public offering.
Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering.